Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development
Reference number: GID-TA11458
Expected publication date: TBC
The Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma.
Following on from advice received from the company, timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.